Macular degeneration (age-related)- pegaptanib and ranibizumab: Response to consultee, commentator and public comments on the ACD and comments from website consultation
Macular degeneration (age-related)- pegaptanib and ranibizumab: Response to public comments on the first Appraisal Consultation Document
Macular degeneration (age-related)- pegaptanib and ranibizumab: Response to consultee and commentator comments on the first Appraisal Consultation Document
Macular degeneration (age-related)- pegaptanib and ranibizumab: Response to public comments on the second Appraisal Consultation Document
Macular degeneration (age-related)- pegaptanib and ranibizumab: Response to consultee and commentator comments on the second Appraisal Consultation Document
This page was last updated: 30 March 2010